BTC$59,450.00-0.42%
ETH$1,586.14+0.82%
USDT$0.9984+0.00%
BNB$552.58+0.38%
USDC$0.9997+0.00%
XRP$1.05+0.33%
SOL$73.91+2.94%
TRX$0.3196-0.68%
FIGR_HELOC$1.05+2.60%
HYPE$66.18+6.58%
DOGE$0.0724-0.01%
RAIN$0.0159+2.31%
USDS$0.99940.00%
LEO$9.53+1.06%
ZEC$399.33+5.86%
XLM$0.1847+7.26%
BTC$59,450.00-0.42%
ETH$1,586.14+0.82%
USDT$0.9984+0.00%
BNB$552.58+0.38%
USDC$0.9997+0.00%
XRP$1.05+0.33%
SOL$73.91+2.94%
TRX$0.3196-0.68%
FIGR_HELOC$1.05+2.60%
HYPE$66.18+6.58%
DOGE$0.0724-0.01%
RAIN$0.0159+2.31%
USDS$0.99940.00%
LEO$9.53+1.06%
ZEC$399.33+5.86%
XLM$0.1847+7.26%
Novo Nordisk stock crashed over 20% in premarket trading after the company cut its 2025 forecast for the second time.
UnitedHealth Group shares fell over 5% in premarket trading after missing Q2 earnings expectations and providing disappointing 2025 guidance.
VAPE stock surged in premarket trading following the announcement of a PIPE offering to establish the world's largest publicly listed BNB treasury strategy.
Celcuity's stock surged over 112% in premarket trading following positive Phase 3 trial results for its breast cancer treatment, marking a potential breakthrough in targeted cancer…
As Intel advances its restructuring efforts, market volatility and noisy stock signals are to be expected.
Intel shares plummeted in premarket trading after reporting Q2 EPS of -$0.10, missing expectations by 171.81%.
Similar in spirit to memecoins, these stocks ride the waves of surges and crashes.
Dow Inc. reported a massive Q2 loss of $0.42 per share versus expectations of a $0.12 loss, prompting a 50% dividend cut.
American Airlines shares tumbled over 6% in premarket trading despite beating Q2 earnings expectations, as investors reacted negatively to disappointing third-quarter guidance and reduced full-year profit…
Exposure to Lockheed Martin represents exposure to U.S. hegemony maintenance.
Fiserv stock plunged over 16% despite beating Q2 earnings expectations, as the company lowered its full-year organic revenue growth guidance and showed weakness in its merchant…
Abivax shares surged over 400% in premarket trading after announcing positive Phase 3 results for its ulcerative colitis drug obefazimod.
GM beat Q2 2025 earnings expectations but shares fell 7% due to $1.1 billion tariff impact and margin compression concerns.